Synchron has raised US$200 million via a Series D financing round, with this funding set to be used to accelerate commercialisation of the company’s first-generation Stentrode brain-computer interface (BCI) platform while also advancing development of a “next-generation, transcatheter, high-channel whole-brain interface”.
In addition to accelerating pivotal trials and preparing for the commercial launch of its Stentrode BCI system, Synchron states in a press release that—bolstered by this Series D funding—it will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs.
The round was led by Double Point Ventures alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS. New investors include the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs and IQT.
The financing brings Synchron’s total funding to US$345 million, as reported in the company’s recent release.
The Stentrode BCI platform is described by Synchron as the “world’s first” endovascular BCI, designed to translate brain activity into digital commands without the need for open brain surgery. Placed via a non-surgical catheter procedure, the Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices. Across clinical trials in the USA and Australia, Stentrode BCIs have been placed in 10 patients with paralysis to date.
“We’ve built the first non-surgical BCI designed for everyday life for people with paralysis,” said Tom Oxley, Synchron’s chief executive officer (CEO) and founder. “This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field—a next-generation, transcatheter, high-channel whole-brain interface.”
According to Synchron, an expanding cognitive artificial intelligence (AI) division in New York City, USA will be training models that learn from brain data to decode thought in real time. In parallel, its new engineering hub in San Diego, USA has been established to build “the world’s most advanced brain interface”.
“Synchron is building the first truly scalable, minimally invasive BCI that can be deployed in everyday healthcare,” commented Campbell Murray, co-founder and managing partner at Double Point Ventures. “Its fusion of neurovascular access, breakthrough device engineering and adaptive AI marks a fundamental step toward restoring digital agency to people with paralysis.”
“Synchron’s work is expanding the frontier of what’s possible between the human brain and technology,” added Bob Langer, executive chairman at T Rx Capital. “This next phase brings us closer to a future where brain interfaces can potentially unlock entirely new dimensions for healthcare.”
